These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 26565547)
1. Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome. Tessaris D; Matarazzo P; Lala R; Defabianis P J Pediatr Endocrinol Metab; 2016 Mar; 29(3):333-6. PubMed ID: 26565547 [TBL] [Abstract][Full Text] [Related]
2. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526 [TBL] [Abstract][Full Text] [Related]
3. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE. Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490 [TBL] [Abstract][Full Text] [Related]
4. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538 [TBL] [Abstract][Full Text] [Related]
5. Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature. Nadella S; Mupparapu M; Akintoye SO Quintessence Int; 2022 Jun; 53(7):616-623. PubMed ID: 35674165 [TBL] [Abstract][Full Text] [Related]
6. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. Leet AI; Chebli C; Kushner H; Chen CC; Kelly MH; Brillante BA; Robey PG; Bianco P; Wientroub S; Collins MT J Bone Miner Res; 2004 Apr; 19(4):571-7. PubMed ID: 15005844 [TBL] [Abstract][Full Text] [Related]
8. Fibrous dysplasia & McCune-Albright syndrome: an experience from a tertiary care centre in north India. Bhadada SK; Bhansali A; Das S; Singh R; Sen R; Agarwal A; Mittal BR; Nahar U; Dutta P; Khandelwal N Indian J Med Res; 2011 May; 133(5):504-9. PubMed ID: 21623035 [TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome. Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402 [TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788 [TBL] [Abstract][Full Text] [Related]
11. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. Mavrokokki T; Cheng A; Stein B; Goss A J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586 [TBL] [Abstract][Full Text] [Related]
12. Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia. Thomsen MD; Rejnmark L Calcif Tissue Int; 2014 Apr; 94(4):384-95. PubMed ID: 24390518 [TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Brown JJ; Ramalingam L; Zacharin MR Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397 [TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. Favia G; Pilolli GP; Maiorano E J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275 [TBL] [Abstract][Full Text] [Related]
15. Eight-year follow-up of a girl with McCune-Albright syndrome. Aycan Z; Önder A; Çetinkaya S J Clin Res Pediatr Endocrinol; 2011; 3(1):40-2. PubMed ID: 21448334 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738 [TBL] [Abstract][Full Text] [Related]
17. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome]. Pfeilschifter J; Ziegler R Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942 [TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405 [TBL] [Abstract][Full Text] [Related]
19. Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort. Utriainen P; Valta H; Björnsdottir S; Mäkitie O; Horemuzova E Front Endocrinol (Lausanne); 2018; 9():96. PubMed ID: 29599748 [TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Lesclous P; Abi Najm S; Carrel JP; Baroukh B; Lombardi T; Willi JP; Rizzoli R; Saffar JL; Samson J Bone; 2009 Nov; 45(5):843-52. PubMed ID: 19631301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]